D. E. Shaw & Co., Inc. - PUMA BIOTECHNOLOGY INC ownership

PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 121 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.

Quarter-by-quarter ownership
D. E. Shaw & Co., Inc. ownership history of PUMA BIOTECHNOLOGY INC
ValueSharesWeighting
Q4 2022$559,138
-56.2%
132,184
-75.5%
0.00%
-50.0%
Q3 2022$1,276,000
-53.4%
538,544
-43.9%
0.00%
-33.3%
Q2 2022$2,736,000
-5.6%
960,072
-4.6%
0.00%0.0%
Q1 2022$2,898,000
+29.5%
1,005,983
+36.7%
0.00%
+50.0%
Q4 2021$2,237,000
+535.5%
735,962
+1364.0%
0.00%
Q3 2021$352,000
-65.6%
50,272
-54.9%
0.00%
-100.0%
Q2 2021$1,024,000
+31.3%
111,506
+39.0%
0.00%0.0%
Q1 2021$780,000
+20.6%
80,196
+27.1%
0.00%
Q4 2020$647,000
+9.5%
63,109
+7.8%
0.00%
Q3 2020$591,000
-74.0%
58,517
-73.2%
0.00%
-100.0%
Q2 2020$2,277,000
+46.3%
218,311
+18.4%
0.00%0.0%
Q1 2020$1,556,000
-55.1%
184,393
-53.5%
0.00%
-50.0%
Q4 2019$3,466,000
-0.9%
396,119
+22.0%
0.00%0.0%
Q3 2019$3,496,000
-33.0%
324,668
-21.0%
0.00%
-42.9%
Q2 2019$5,221,000
-72.8%
410,800
-17.0%
0.01%
-72.0%
Q1 2019$19,210,000
+756.4%
495,226
+349.2%
0.02%
+733.3%
Q4 2018$2,243,000
-83.7%
110,235
-63.3%
0.00%
-81.2%
Q3 2018$13,760,000
-72.1%
300,102
-64.0%
0.02%
-75.0%
Q2 2018$49,304,000
-48.8%
833,544
-41.1%
0.06%
-51.1%
Q1 2018$96,362,000
-4.4%
1,416,045
+38.8%
0.13%
-5.8%
Q4 2017$100,836,000
+504.4%
1,020,078
+632.2%
0.14%
+434.6%
Q3 2017$16,683,000
-9.2%
139,311
-33.7%
0.03%
-13.3%
Q2 2017$18,369,000
+324.5%
210,168
+80.7%
0.03%
+275.0%
Q1 2017$4,327,000
+1445.4%
116,309
+1173.5%
0.01%
Q4 2016$280,000
-92.8%
9,133
-84.2%
0.00%
-100.0%
Q3 2016$3,864,000
-4.4%
57,628
-57.5%
0.01%0.0%
Q2 2016$4,043,000
+42.1%
135,727
+40.1%
0.01%
+16.7%
Q1 2016$2,845,000
-82.8%
96,857
-54.1%
0.01%
-76.0%
Q4 2015$16,533,000
+188.5%
210,870
+177.3%
0.02%
+212.5%
Q3 2015$5,730,000
+1946.4%
76,032
+3068.0%
0.01%
Q2 2015$280,000
-98.7%
2,400
-97.3%
0.00%
-100.0%
Q1 2015$20,907,000
+77.9%
88,548
+42.6%
0.03%
+113.3%
Q4 2014$11,750,000
+39.3%
62,080
+75.6%
0.02%
+25.0%
Q3 2014$8,435,000
+2901.8%
35,355
+731.3%
0.01%
Q2 2014$281,000
-92.9%
4,253
-88.7%
0.00%
-100.0%
Q1 2014$3,932,000
+80.9%
37,758
+79.9%
0.01%
+100.0%
Q4 2013$2,173,000
+471.8%
20,985
+196.3%
0.00%
+200.0%
Q3 2013$380,000
+18.4%
7,083
-2.1%
0.00%0.0%
Q2 2013$321,0007,2330.00%
Other shareholders
PUMA BIOTECHNOLOGY INC shareholders Q2 2021
NameSharesValueWeighting ↓
GREAT POINT PARTNERS LLC 1,300,000$12,636,0002.61%
AIGH Capital Management LLC 964,590$9,376,0001.97%
Worth Venture Partners, LLC 226,758$2,204,0001.07%
Camber Capital Management LP 2,555,000$24,835,0000.85%
Palo Alto Investors LP 1,392,997$13,540,0000.77%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 3,769,795$36,642,0000.77%
GLOBEFLEX CAPITAL L P 428,680$4,167,0000.76%
Zebra Capital Management LLC 34,243$333,0000.37%
Sofinnova Investments, Inc. 344,917$3,353,0000.20%
RICE HALL JAMES & ASSOCIATES, LLC 605,792$5,888,0000.19%
View complete list of PUMA BIOTECHNOLOGY INC shareholders